Chemosensitization by Antisense Oligonucleotides Targeting MDM2

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|5|1|51-56

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.5, Iss.1, 2005-01, pp. : 51-56

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Novel Antisense Anti-MDM2 Mixed-Backbone Oligonucleotides: Proof of Principle, In Vitro and In Vivo Activities, and Mechanisms

By  

Current Cancer Drug Targets, Vol. 5, Iss. 1, 2005-02 ,pp. : 43-49

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting Human Telomerase by Antisense Oligonucleotides and Ribozymes: An Update

By  

Medicinal Chemistry Reviews - Online, Vol. 1, Iss. 4, 2004-10 ,pp. : 413-417

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting the Expression of Anti-Apoptotic Proteins by Antisense Oligonucleotides

By  

Current Drug Targets, Vol. 2, Iss. 2, 2001-06 ,pp. : 167-180

Bentham Science Publishers

Access to resources Recommend Favorite

2'-Modified Oligonucleotides for Antisense Therapeutics

By  

Current Topics in Medicinal Chemistry, Vol. 7, Iss. 7, 2007-04 ,pp. : 641-649

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting MDM2 and MDMX in Retinoblastoma

By  

Current Cancer Drug Targets, Vol. 7, Iss. 7, 2007-11 ,pp. : 689-695

Bentham Science Publishers

Access to resources Recommend Favorite